Systematic benefit-risk study deems remdesivir a ‘favourable’ COVID-19 treatment
The Drug Safety Research Unit (DSRU), based in Southampton, UK, has found a ‘favourable’ profile for Gilead’s antiviral drug remdesivir in COVID-19 after conducting a systematic benefit-risk analysis.
The study, published in the journal Drug Safety, recorded all possible benefits and risks for COVID-19 patients receiving remdesivir obtained by evaluating public data from peer reviewed journals and some pre-publication clinical trial data.
It found the benefits of remdesivir included quicker recovery time, with one study showing median recovery time for remdesivir patients of 11 days compared with 15 days for those on placebo.
The analysis also found slight reductions in mortality, although this was not statistically significant, with 8% of remdesivir patients dying compared to 11.6% in patients given a placebo.
Read more: http://www.pharmatimes.com/news/systematic_benefit-risk_study_deems_remdesivir_a_favourable_covid-19_treatment_1352628
The study, published in the journal Drug Safety, recorded all possible benefits and risks for COVID-19 patients receiving remdesivir obtained by evaluating public data from peer reviewed journals and some pre-publication clinical trial data.
It found the benefits of remdesivir included quicker recovery time, with one study showing median recovery time for remdesivir patients of 11 days compared with 15 days for those on placebo.
The analysis also found slight reductions in mortality, although this was not statistically significant, with 8% of remdesivir patients dying compared to 11.6% in patients given a placebo.
Read more: http://www.pharmatimes.com/news/systematic_benefit-risk_study_deems_remdesivir_a_favourable_covid-19_treatment_1352628
